Tomas Kalincik

Yale University

Australia

Research Interests

Explore related searches

Professors in Australia

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (21)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Collaborators (12)

Maria José Sá

Universidade da Beira Interior Faculdade de Ciências da Saúde

PORTUGAL

View details

Ingrid van der Mei

University of Tasmania

AUSTRALIA

View details

Michael Zhong

MONASH UNIVERSITY

AUSTRALIA

View details

francesco patti

Professore Associato di Neurologia SSD Med 26

University of Catania

ITALY

View details

Alessandra Lugaresi

Associate Professor

ITALY

View details

Yi Chao Foong

University of Tasmania

AUSTRALIA

View details

Ilya Kister

Professor

NYU School of Medicine

UNITED STATES

View details

Guy Laureys

Ghent University Hospital

BELGIUM

View details

Izanne Roos

University of Melbourne

AUSTRALIA

View details

Jeannette Lechner-Scott

Hunter New England Local Health District

AUSTRALIA

View details

Daniel Merlo

Monash University Malaysia.

AUSTRALIA

View details

Stephen Reddel

University of Sydney

AUSTRALIA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Tomas Kalincik

Research Interests

Explore related searches

Contact this professor

Articles (21)

Long-term acceptability of MSReactor digital cognitive monitoring among people living with multiple sclerosis

Longitudinal Trajectories of Digital Cognitive Biomarkers for Multiple Sclerosis

Longitudinal trajectories of digital upper limb biomarkers for multiple sclerosis

Disease course after pregnancy in women with progressive multiple sclerosis symptoms

Persistent progression independent of relapse activity in multiple sclerosis

Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis

Explainable time-to-progression predictions in multiple sclerosis

Efficacy of natalizumab in secondary progressive multiple sclerosis: analysis of two phase III trials

The topography of infratentorial lesions in depression and anxiety in multiple sclerosis

Approach to Managing the Initial Presentation of Multiple Sclerosis

Observational studies of treatment effectiveness in neurology

Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry

Prediction of relapse activity when switching to cladribine for multiple sclerosis

Early Treatment for Multiple Sclerosis

Rates of John Cunningham virus seroconversion greatly reduced in natalizumab‐treated patients during COVID‐19‐related lockdowns

The Patient‐Determined Disease Steps scale is not interchangeable with the Expanded Disease Status Scale in mild to moderate multiple sclerosis

Early Treatment for Multiple Sclerosis: Time Is Brain

Seizure risk in multiple sclerosis patients treated with disease-modifying therapy: A systematic review and network meta-analysis

Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS

Superior effects of natalizumab versus other DMTs on patient-reported outcomes in people with multiple sclerosis

Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis

Collaborators (12)

Maria José Sá

Ingrid van der Mei

Michael Zhong

francesco patti

Alessandra Lugaresi

Yi Chao Foong

Ilya Kister

Guy Laureys

Izanne Roos

Jeannette Lechner-Scott

Daniel Merlo

Stephen Reddel

Make your next move.